Targeting STAT3 in cancer immunotherapy

S Zou, Q Tong, B Liu, W Huang, Y Tian, X Fu - Molecular cancer, 2020 - Springer
As a point of convergence for numerous oncogenic signaling pathways, signal transducer
and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune …

Therapeutically exploiting STAT3 activity in cancer—using tissue repair as a road map

J Huynh, A Chand, D Gough, M Ernst - Nature Reviews Cancer, 2019 - nature.com
The tightly orchestrated temporal and spatial control of signal transducer and activator of
transcription 3 (STAT3) activity in epithelial, immune and stromal cells is critical for wound …

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

Y Hu, Z Dong, K Liu - Journal of Experimental & Clinical Cancer Research, 2024 - Springer
Signal transducer and activator of transcription 3 (STAT3) is a transcriptional factor involved
in almost all cancer hallmark features including tumor proliferation, metastasis …

Multicellular effects of STAT3 in non-small cell lung cancer: Mechanistic insights and therapeutic opportunities

S Parakh, M Ernst, AR Poh - Cancers, 2021 - mdpi.com
Simple Summary Persistent activation of STAT3 is frequently observed in non-small cell lung
cancer and is associated with a poor prognosis. Given the multifaceted role of STAT3 …

Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma

Q Zhang, W Ding, J Mo, SM Ou-Yang, Z Lin… - Acta Pharmacologica …, 2024 - nature.com
Signal transducer and activator of transcription 3 (STAT3) plays an important role in the
occurrence and progression of tumors, leading to resistance and poor prognosis. Activation …

[HTML][HTML] Dual STAT‑3 and IL‑6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL‑6/IL …

A Méndez‑Clemente, A Bravo‑Cuellar… - Oncology …, 2022 - spandidos-publications.com
Prostate cancer (PCa) is a key public health problem worldwide; at diagnosis, a high
percentage of patients exhibit tumor cell invasion of adjacent tissue. STAT‑3, IL‑6 receptor …

TYK2: an upstream kinase of STATs in cancer

K Wöss, N Simonović, B Strobl, S Macho-Maschler… - Cancers, 2019 - mdpi.com
In this review we concentrate on the recent findings describing the oncogenic potential of the
protein tyrosine kinase 2 (TYK2). The overview on the current understanding of TYK2 …

Mechanisms of immune evasion and immune modulation by lymphoma cells

T Menter, A Tzankov - Frontiers in oncology, 2018 - frontiersin.org
Purpose Targeting cancer cells by modulating the immune system has become an important
new therapeutic option in many different malignancies. Inhibition of CTLA4/B7 and …

Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

RAL de Groen, R van Eijk, S Böhringer… - Blood …, 2021 - ashpublications.org
Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal lymphoma
subtype. This retrospective study elucidates the currently unknown genetic background of a …

[HTML][HTML] CTLA-4 and its inhibitors in esophageal cancer: efficacy of therapy and potential mechanisms of adverse events

C Tian, X Wang, S Zhang - American Journal of Cancer Research, 2023 - ncbi.nlm.nih.gov
Esophageal cancer is one of the most prevalent diseases in the world, and its prognosis
remains poor. Surgery, chemotherapy, and radiotherapy are the most common treatment …